trending Market Intelligence /marketintelligence/en/news-insights/trending/5Yw3rGmovh-3UIJsF2gvCA2 content esgSubNav
In This List

US FDA approves Dimension Therapeutics' application for urea cycle disorder drug

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


US FDA approves Dimension Therapeutics' application for urea cycle disorder drug

The U.S. FDA accepted Dimension Therapeutics Inc.'s investigational new drug application for DTX301 to treat ornithine transcarbamylase deficiency, a genetic disorder that causes ammonia to accumulate in the blood.

Dimension expects to start a phase 1/2 clinical trial to evaluate the urea cycle disorder drug in patients with the deficiency by the end of 2016.